MS4A1 and diffuse large B-cell lymphoma: The application is based on the clinical data obtained from studies including Phase 3‐ safety & efficacy of IBI301 along with chemotherapy and phase 1 pharmacokinetics & safety assessment in patients with untreated CD20‐positive diffuse large B‐cell lymphoma (DLBCL).135